YMYoshihiko Murata

Yoshihiko Murata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoshihiko Murata has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Ann R Falsey

    Infectious Diseases Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester Genera Hospital, New York, USA

    1 shared publication
  • Ann R. Falsey

    Department of Medicine, University of Rochester School of Medicine and Dentistry and Infectious Diseases Unit, Department of Medicine, Rochester General Hospital, Rochester, New York

    1 shared publication
  • Edward E. Walsh

    Department of Medicine, University of Rochester School of Medicine and Dentistry and Infectious Diseases Unit, Department of Medicine, Rochester General Hospital, Rochester, New York

    1 shared publication

Latest Publications

  • Respiratory syncytial virus infection in adults

    by Yoshihiko Murata

    Respiratory syncytial virus has increasingly been recognized as a clinically significant cause of respiratory tract infections in adults, especially among the elderly and the immunocompromised. Advances in molecular diagnostic methods have enabled rapid diagnosis of respiratory syncytial virus for clinical and epidemiological studies. Recent reports focus on clinical, immunological, and/or radiographic characterizations of respiratory syncytial virus infection in adults, particularly in hospitalized patients and those with underlying chronic obstructive pulmonary disease, and therapeutic and prophylactic use of antiviral agents in immunocompromised adults. Respiratory syncytial virus vaccine development remains a high priority, with the testing of genetically engineered live attenuated vaccines leading to further insights into the pathogenesis of respiratory syncytial virus in adults. Further studies are necessary to elucidate the pathogenesis and immune response against respiratory syncytial virus in adults. The significant burden of respiratory syncytial virus-induced disease in adults and the limited number of approved antiviral agents reinforce the need to develop a respiratory syncytial virus vaccine.


  • Open Access

    Pulmonary Complications of Interpandemic Influenza A in Hospitalized Adults

    by Yoshihiko Murata, Edward E. Walsh, Ann R. Falsey

    Background. To define the pulmonary complications of influenza during the current interpandemic period, we reviewed clinical, laboratory, and radiogr


  • Respiratory Syncytial Virus Infection in Adults

    by Yoshihiko Murata, Ann R Falsey

    Originally considered as only a paediatric pathogen, respiratory syncytial virus (RSV) has recently been shown to be a significant cause of respiratory illness among elderly and high-risk adults. Approximately 170,000 hospitalizations and 10,000 deaths associated with RSV occur annually in people over the age of 65 years in the United States. Although rhinorrhoea and wheezing are common symptoms among adults, the clinical syndrome associated with RSV is not distinctive and thus laboratory methods are required for specific diagnosis. Presently, the combination of reverse transcription PCR and enzyme immunoassay serology offers the best sensitivity and specificity for diagnosis of RSV. Treatment options are limited at present, with inhaled ribavirin being the only licensed drug for use in hospitalized children. Vaccines against RSV remain an unachieved goal. Promising new agents that inhibit the virus-cell fusion, cell-cell fusion, or viral gene expression are currently in development.